If you are trying to figure out whether to hold onto your Kenvue shares, add more to your portfolio, or sit this one out, you are definitely not alone. Investors have watched Kenvue’s stock price take a hit lately,

Kenvue rebuked claims of a connection between autism and acetaminophen and said it is “deeply concerned with the health risk this poses for expecting mothers.”

Shares of consumer healthcare firm Kevnue dropped to a record low during regular trading Monday, then made up some ground afterhours as President Trump warned that acetaminophen, the active ingredient in Kenvue's Tylenol,

Earlier this week, the Trump administration publicly warned of a possible link between prenatal Tylenol use and autism, prompting Kenvue, the maker of Tylenol, to issue a firm denial and highlight scientific consensus against such claims.

Kenvue shares declined on Tylenol autism reports, creating a long-term buying opportunity for savvy investors. Click here to read my analysis on KVUE stock.

Kenvue (NYSE: KVUE) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of their recent ratings,

Shares of Kenvue Inc. slid 4.09% to $16.17 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.50% to 6,604.72 and Dow Jones Industrial Average falling 0.

Kenvue's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Learn more about KVUE stock here.